The potential of EZH2 expression to facilitate treatment choice in stage II colorectal adenocarcinoma
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.High Enhancer of zeste homolog 2 (EZH2) expression in stage II colorectal cancer (CRC) patients indicates a better response to adjuvant chemotherapy. EZH2 may identify early-stage CRC patients who benefit from combined surgery and chemotherapy.
Area Of Science
- Oncology
- Molecular Biology
- Cancer Research
Background
- Current criteria for adjuvant therapy selection in stage II colorectal carcinoma (CRC) are inadequate.
- Enhancer of zeste homolog 2 (EZH2) is over-expressed in CRC, but its role in survival, particularly in stage II, is unclear.
Purpose Of The Study
- To investigate the clinical significance of EZH2 expression in stage II CRC.
- To determine if EZH2 expression can predict response to adjuvant therapy.
Main Methods
- Retrospective review of stage II CRC cases (2015-2018).
- Immunohistochemistry analysis of EZH2 expression.
- Kaplan-Meier survival analysis.
Main Results
- High EZH2 expression was observed in 60.63% of stage II CRC tumors.
- High EZH2 expression correlated with improved overall survival (OS) in patients receiving adjuvant chemotherapy compared to surgery alone.
- No significant impact of treatment choice on survival was observed in patients with low EZH2 expression.
Conclusions
- EZH2 expression may serve as a biomarker to identify stage II CRC patients who benefit from adjuvant chemotherapy.
- Further large-scale studies are needed to validate EZH2's predictive value.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.